Maternal circulating SPINT1 is reduced in small-for-gestational age pregnancies at 26 weeks: Growing up in Singapore towards health outcomes (GUSTO) cohort study

Accepted/In Press date: 26 May 2021

e-pub ahead of print date: 1 June 2021

Published date: July 2021

Additional Information: Funding Information: Funding for this work was provided by the National Health and Medical Research Council (#1065854, #1183854, #116071), National Health and Medical Research Council Fellowships to TKL (#1159261) and ST (#1136418), and the Singapore National Research Foundation under its Translational and Clinical Research (TCR) Flagship Programme and administered by the Singapore Ministry of Health's National Medical Research Council (NMRC), Singapore [NMRC/TCR/004-NUS/2008, NMRC/TCR/012-NUHS/2014]. Additional funding was provided by the Singapore Institute for Clinical Sciences, Agency for Science Technology and Research (A*STAR), Singapore.TKL, TM, SW and ST hold a provisional patent (PCT/AU2019/050,516) relating to the use of SPINT1 and syndecan as diagnostic markers in pregnancy. KMG, PDG and YSC have received reimbursement for speaking at conferences sponsored by companies selling nutritional products, and is part of an academic consortium that has received research funding from Abbott Nutrition, Nestec, BenevolentAI Bio Ltd. and Danone. The remaining authors have no conflicts of interest to declare.KMG is supported by the UK Medical Research Council (MC_UU_12011/4), the National Institute for Health Research (NIHR Senior Investigator (NF?SI-0515-10042), NIHR Southampton 1000DaysPlus Global Nutrition Research Group (17/63/154) and NIHR Southampton Biomedical Research Centre (IS-BRC-1215-20004)), the European Union (Erasmus+ Programme ImpENSA 598488-EPP-1-2018-1-DE-EPPKA2-CBHE-JP) and the British Heart Foundation (RG/15/17/3174). Funding Information: Funding for this work was provided by the National Health and Medical Research Council (#1065854, #1183854, #116071), National Health and Medical Research Council Fellowships to TKL (#1159261) and ST (#1136418), and the Singapore National Research Foundation under its Translational and Clinical Research (TCR) Flagship Programme and administered by the Singapore Ministry of Health's National Medical Research Council ( NMRC ), Singapore [ NMRC /TCR/004- NUS /2008, NMRC /TCR/012- NUHS /2014]. Additional funding was provided by the Singapore Institute for Clinical Sciences , Agency for Science Technology and Research ( A*STAR ), Singapore. Funding Information: TKL, TM, SW and ST hold a provisional patent (PCT/AU2019/050516) relating to the use of SPINT1 and syndecan as diagnostic markers in pregnancy. KMG, PDG and YSC have received reimbursement for speaking at conferences sponsored by companies selling nutritional products, and is part of an academic consortium that has received research funding from Abbott Nutrition, Nestec, BenevolentAI Bio Ltd. and Danone. The remaining authors have no conflicts of interest to declare. Funding Publisher Copyright: © 2021 Copyright: Copyright 2021 Elsevier B.V., All rights reserved.

Keywords: Biomarker, Fetal growth restriction, SGA, SPINT1

Local EPrints ID: 449780

URI: http://eprints.soton.ac.uk/id/eprint/449780

DOI: doi:10.1016/j.placenta.2021.05.007

ISSN: 0143-4004

PURE UUID: 8e6267ef-0867-4532-97ce-5ba4b41b7b62

ORCID for Keith Godfrey: orcid.org/0000-0002-4643-0618

Date deposited: 17 Jun 2021 16:30

Last modified: 17 Mar 2024 02:38